News|Articles|November 17, 2026

FDA approves Cosentyx as first anti-IL-17 biologic for polymyalgia rheumatica

Author(s)Logan Lutton
Listen
0:00 / 0:00

Key Takeaways

  • Regulatory clearance positions secukinumab as the first IL-17 biologic for PMR, addressing relapse-prone, steroid-dependent disease and the morbidity associated with prolonged glucocorticoid exposure.
  • REPLENISH showed sustained remission at week 52 in 40.5% with secukinumab 150 mg versus 20.5% with placebo after a 24-week taper, alongside steroid-sparing outcomes.
SHOW MORE

The FDA approved Cosentyx for polymyalgia rheumatica after 40.5% of trial patients reached sustained remission at week 52 vs. 20.5% on placebo.

Adults with polymyalgia rheumatica (PMR) who have not responded adequately to corticosteroids or who cannot tolerate a steroid taper have a new treatment option after the FDA approved Cosentyx (secukinumab) 150 mg for the condition, Novartis announced today in a news release. Cosentyx is the first and only anti-IL-17 biologic approved for the disease.

PMR is an inflammatory disease that primarily affects adults over 50 and is characterized by acute pain and stiffness in the shoulders, neck and hips. Approximately 5 out of every 10,000 people in the United States are living with PMR. Long-term steroid use is the current standard of care, but relapses are frequent, affecting up to 40% of patients in the first year. Extended steroid exposure also increases the risk of osteoporosis, cardiovascular disease and diabetes.

What the REPLENISH trial found for Cosentyx in PMR

The approval is based on REPLENISH, a placebo-controlled Phase III study across 27 countries that tested Cosentyx 300 mg and 150 mg, each with a 24-week steroid taper. The data were published in the New England Journal of Medicine and presented at the European Alliance of Associations for Rheumatology Congress earlier this year.

The trial met its primary end point. At week 52, after completing the steroid taper, 40.5% of patients on Cosentyx 150 mg had achieved sustained remission, compared with 20.5% of those on placebo. Key secondary end points included complete sustained remission, the adjusted annual cumulative steroid dose and time to first escape or rescue treatment. Novartis said Cosentyx demonstrated steroid-sparing effects vs. placebo.

“Patients with PMR are at increased risk of poor outcomes related to steroids, and the prospect of months or years of additional steroids is disheartening,” said John Stone, M.D., M.P.H., professor of medicine at Harvard Medical School and Massachusetts General Hospital and global principal investigator for the REPLENISH trial. “For too long, treatment options beyond glucocorticoids have been limited.”

Novartis said safety in the trial was consistent with the drug’s established profile. Serious side effects occurred in 15.9% of patients in the Cosentyx 150-mg group and 14.2% of those in the placebo group. Patients on Cosentyx 150 mg had higher rates of hypersensitivity reactions, including eczema, dermatitis, rash and urticaria (14% vs. 9%), and urinary tract infections (13% vs. 7%) than those on placebo. One patient in the 150-mg group had a serious urinary tract infection, and a fatal case of cryptococcal meningitis occurred in a patient treated with Cosentyx.

Where Cosentyx fits in the PMR treatment landscape

Cosentyx is not the first PMR biologic. In 2023, the FDA approved Kevzara (sarilumab), an IL-6 receptor blocker from Sanofi and Regeneron, for the same population of patients with an inadequate response to corticosteroids or who cannot tolerate a taper. In its Phase III SAPHYR trial, 28% of patients on Kevzara achieved sustained remission at 52 weeks vs. 10% on placebo. The trials used different designs and taper schedules, so their results are not directly comparable.

Cosentyx is also approved for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa. The PMR indication is already approved in the European Union, and reviews are ongoing in Japan and other countries.

What the Cosentyx PMR approval means for payers

The approval comes as Medicare prepares to set a negotiated price for Cosentyx. The Centers for Medicare and Medicaid Services selected the drug for the third cycle of the Medicare Drug Price Negotiation Program, with negotiated prices taking effect in 2028. The list price for Cosentyx is $8,492.03 a month for either self-injection dose strength and $4,579.12 per IV infusion, according to Novartis. Last year, Novartis began offering the drug to cash-paying patients at a 55% discount off list price.

“PMR can make remarkably ordinary things hard: getting out of bed, getting dressed, lifting your arms, getting through the day. For years, patients have had too few treatment options,” said Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation and CreakyJoints. “The approval of secukinumab offers patients and their clinicians a new therapeutic option and the opportunity for more individualized care.”


Related to this article